HBV treatment
US9790502B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 11, 2016 |
| Grant date | Oct 17, 2017 |
| Priority date | — |
| Expiry date | Jul 11, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/531
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.